Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter's winners and losers.

The drugmaker reported disappointing data from a mid-stage trial for its weight-loss pill monlunabant last year, followed by results for a separate experimental shot called CagriSema that missed ...

Products are independently selected by our editors. We may earn an affiliate commission from links. A Pierce & Ward room has an unmistakable presence. Thoughtfully layered patterns, plush textures ...

Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight loss in patients part of the 68-week REDEFINE 1 study. In REDEFINE 2, patients lost 15.1% of weight in the same time ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. Headline results from a REDEFINE-2 ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight ...

The company is developing CagriSema as a weight management medicine. In December, Novo Nordisk reported that CagriSema helped patients lose, on average, 22.7% of their body weight in a phase 3 study.

The market’s focus is narrow, but step outside the spotlight and you’ll find where real momentum is building LONDON, United Kingdom, March 27, 2025 (EZ Newswire) -- ValueTheMarkets, a trusted ...

CagriSema has had parallel studies completed, setting it up to be available for both diabetes and obesity treatment. What's more, the Danish giant has just announced a US$2-billion deal with ...